City Therapeutics (NASDAQ:CTY) Stock Price Down 5% – What’s Next?

City Therapeutics, Inc. (NASDAQ:CTY) dropped 5% on Wednesday. The stock traded as low as $18.09 and last traded at $18.63. 345,963 shares traded hands during trading, an increase of 27% from the average daily volume of 272,810 shares. The stock had previously closed at $19.62.

Analysts Set New Price Targets

A number of research firms recently issued reports on CTY. Jefferies Financial Group assumed coverage on City Therapeutics in a report on Tuesday. They set a “buy” rating and a $32.00 price objective for the company. Stifel Nicolaus started coverage on City Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $34.00 target price on the stock. Oppenheimer initiated coverage on shares of City Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $46.00 price objective for the company. Zacks Research assumed coverage on City Therapeutics in a report on Wednesday. They set a “hold” rating on the stock. Finally, Wall Street Zen raised shares of City Therapeutics to a “hold” rating in a research report on Saturday, October 24th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, City Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $37.33.

City Therapeutics Stock Down 6.2%

Insider Buying and Selling

In related news, Director Robert Nelsen purchased 170,000 shares of City Therapeutics stock in a transaction dated Monday, October 19th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $3,060,000.00. Following the transaction, the director owned 13,692,507 shares in the company, valued at approximately $246,465,126. The trade was a 1.26% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Arch Venture Partners Xii, Llc purchased 170,000 shares of the company’s stock in a transaction dated Monday, October 19th. The stock was purchased at an average price of $18.00 per share, with a total value of $3,060,000.00. Following the transaction, the insider owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. This represents a 1.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

About City Therapeutics

City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.